The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

"We appreciate the Chinese government's strong commitment to deepening reforms and expanding high-standard opening-up, with a ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...

Astellas Pharma (OTCPK:ALPMY) and YASKAWA Electric signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

Get ready to see more of Henry Winkler on TV talking about geographic atrophy (GA). | During a quarterly conference call, as ...

Based on the memorandum of agreement signed in May, 2024, Astellas and YASKAWA have been advancing discussions toward establishing a joint venture to leverage their mutual strengths and accelerate ...

Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the ...

"As a multinational pharmaceutical company, Astellas has benefited from these supportive policies in its business growth in China, and we remain confident in the country's continuous endeavors to ...

Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions- TOKYO, March 5, 2025 /PRNewswire/ -- Astellas ...